• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Vector borne diseases
 

Vector borne diseases

on

  • 2,905 views

Vector-borne diseases-Malaria, Filariasis, Dengue, JE, YF, Chikungunya, KFD, Leishmaniasis and the national program against vector-borne diseases NVBDCP.

Vector-borne diseases-Malaria, Filariasis, Dengue, JE, YF, Chikungunya, KFD, Leishmaniasis and the national program against vector-borne diseases NVBDCP.

Statistics

Views

Total Views
2,905
Views on SlideShare
2,901
Embed Views
4

Actions

Likes
3
Downloads
232
Comments
3

2 Embeds 4

http://www.slashdocs.com 3
http://users.unjobs.org 1

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel

13 of 3 previous next Post a comment

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Vector borne diseases Vector borne diseases Presentation Transcript

    • MALARIA
    • What is Malaria?• You know it. Well done.• And for those who think they know little about malaria, follow us for next 35 minutes and go through your book at home.
    • MALARIATHE PARASITE
    • • Plasmodium falciparum• Plasmodium vivax• Plasmodium ovale – Tropical Africa• Plasmodium malariae – Karnataka
    • MALARIATHE VECTOR
    • Some species• An. culicifacies• An. fluviatilis• An. stephensi• An. minimus• An. philippinensis• An. sundaicus• An. maculatus
    • Factors which determine vectorial importance of mosquitoes• DENSITY – Critical density- below which effective transmission cannot be maintained in a community • An. culicifacies- high density • An. fluviatilis- low density• LIFE SPAN
    • • CHOICE OF HOST – Anthrophilic species like An. fluviatilis are better vectors of malaria than zoophilic species• RESTING HABITS – Endophily – Exophily• BREEDING HABITS• TIME OF BITING• RESISTANCE TO INSECTICIDES
    • MALARIATHE DISEASE
    • Reservoir of infection• Human reservoir – Harbors the sexual forms (gametocytes) of the parasite• P. malariae – Chimpanzees in tropical Africa
    • • A patient can be a carrier of several plasmodia species at the same time• Children are more likely to be gametocyte carriers than adults. The child is thus epidemiologically a better reservoir than the adult.
    • Conditions that must be met before a person can serve as a reservoir• Both male and female gametocytes are present in blood• Gametocytes are mature• Gametocytes are viable• Gametocytes are present in sufficient density to infect mosquitoes (at least 12/cumm of blood)
    • Period of communicability• As long as mature, viable gametocytes exist in circulating blood in sufficient density
    • Mode of transmission• Vector transmission• Direct transmission• Congenital malaria
    • Incubation period• Falciparum – 12 (9-14)• Vivax – 14 (8-17)• Ovale – 17 (16-18)• Malariae – 28 (18-40)
    • Clinical features• Signs and symptoms• Complications – Cerebral malaria – Dehydration – ARF – Collapse – Liver damage – Anemia – GI symptoms – Blackwater fever
    • • Anemia• Splenomegaly• Enlargement of liver• Herpes• Renal complications
    • MALARIAGLOBAL SCENARIO
    • Every minute 2 people die of malaria. Bythe time we will finish this lecturemalaria would have killed180 morepeople.
    • MALARIASOUTH-EAST ASIA REGION
    • MALARIAPREVENTION & CONTROL
    • A. Malaria Vector Control• Integrated Vector Management (IVM)• Indoor Residual Spraying (IRS) Integrated vector management (IVM) is a•rational decision-making process for the Insecticide Treated Nets (ITNs)•optimal use of resources in the management Other methods of – Larviciding vector populations, so as to reduce or – Environmental management approaches to interrupt transmission of vector-borne vector control diseases. – Personal protection measures (includes ITNs) – Fogging or area spraying
    • INSECTICIDESOrgano-Chlorines DDTOrgano- Malathion,Abate, FentPhosphates hion, ChlorpyrifosCarbamates Propoxur, CarbarylSynthetic Tetramethrin, Resmethpyrethroids rin, Allethrin
    • B. Diagnosis• Direct Microscopy• RDTs (Rapid diagnostic tests)
    • • Histidine-rich protein-2 (HRP2)• Parasite-specific lactate dehydrogenase (pLDH)
    • C. Treatment CQ Chloroquine 25 mg/Kg over 3days PLUS Sensitive Primaquine 0.25 mg/kg BW daily for 14 days Vivax CQ ACT PLUS Resistant Primaquine 0.25 mg/kg BW daily for 14 days ACTFalciparum PLUS Primaquine 0.75 mg/kg BW single doseSevere Parenteral Artemesinin Followed by fullMalaria derivatives/Quinine course of ACT
    • • Plasmodium vivax cases – Day 0: T. Chl 10 mg/kg BW (600 mg adult dose) – Day 1: T. Chl 10 mg/kg BW (600 mg adult dose) – Day 2: T. Chl 5 mg/kg BW (300 mg adult dose) PLUS T. Primaquin 0.25 mg/kg BW daily for 14 days
    • ACT (Artesunate Combination Therapy)T. Artesunate 4mg/kg BW daily X 3days PLUST. Sulphadoxine 25 mg/kg BW and T.Pyrimethamin 1.25 mg/kg BW on the first dayResistance to Chloroquine and ACTOral Quinine 10 mg/kg BW and T.Doxycycline 100 mg daily for 3 daysTHEREAFTER T. Primaquin 0.75 mg/kg BWsingle dose
    • 1.Artesunate 2.4 mg/Kg BW IV or IM at 0, 12 & 24 hrs, then daily2.Artemether 3.2 mg/Kg BW at 0, then 1.6 mg.Kg BW per day3.Quinine 20 mg salt/Kg BW at 0 (IV infusion), then 10 mg/Kg BW every 8 hrs
    • D. Intermittent Preventive Treatment
    • E. Malaria vaccines
    • • Pre-erythrocytic vaccines• Blood-stage vaccines• Transmission-blocking vaccines – Pfs25• Cocktail vaccines – SPf66
    • F. Chemoprophylaxis• Travelers from non-endemic areas• Soldiers serving in highly endemic areas• Migrant labourers• Should be complemented by personal protection and environmental measures• Intermittent preventive treatment in pregnancy
    • • For short-term prophylaxis (< 6 weeks) – Doxycycline 100 mg X OD in adults or 1.5 mg/kg BW for children >8 years old. – Started 2 days before travel and continued for 4 weeks after leaving the malarious area. – Contraindicated in pregnant females and children <8 years.• For long-term prophylaxis (>6 weeks) – Mefloquine 5 mg/kg BW (upto 250 mg) weekly – Started 2 weeks before travel and continued till 4 weeks of leaving the malarious area. – Contraindicated in cases with H/O convulsions, neuropsychiatric problems and cardiac conditions.
    • MALARIAINDICATORS
    • • Eradication era – Annual parasite incidence (API) – Annual blood examination rate (ABER) – Annual falciparum incidence (AFI) – Slide positivity rate (SPR) – Slide falciparum rate (SFR)
    • LYMPHATIC FILARIASIS
    • • The term “lymphatic filariasis” covers infection with three closely related nematode worms – Wuchereria bancrofti – Brugia malayi – Brugia timori
    • • Transmitted to man by the bites of infective mosquitoes.• Adult worms live in the lymphatic vessels; their offspring-the microfilariae-circulate in peripheral blood and are available to infect mosquito vectors when they come to feed.
    • FILARIA ENDEMIC DISTRICTS250 Endemic districts in 20 States/UTs Population: 600 Million
    • Agent factorsOrganism VectorsW. bancrofti CulexB. malayi Mansonia, AedesB. timori Anopheles
    • • The Mf display nocturnal periodicity. They appear in large numbers at night and retreat from the blood stream during the day.• The maximum density of Mf in blood is reported between 10 pm and 2 am.
    • Mf W. bancrofti Mf B. malayiGeneral Graceful, Crinkled,appearance sweeping curves secondary curvesLength 244 to 296 µ 177 to 230 µExcretory pore Not prominent ProminentCaudal end Uniformly Kinkled and two tapering to a terminal nuclei delicate point; present no terminal nuclei presentNuclear column Nuclei discrete Smudged
    • The typical vector for Brugia malayi filariasis are mosquito species from thegenera Mansonia and Aedes. During a blood meal, an infected mosquitointroduces third-stage filarial larvae onto the skin of the human host, wherethey penetrate into the bite wound . They develop into adults thatcommonly reside in the lymphatics . The adult worms resemble those ofWuchereria bancrofti but are smaller. Female worms measure 43 to 55 mmin length by 130 to 170 μm in width, and males measure 13 to 23 mm inlength by 70 to 80 μm in width. Adults produce microfilariae, measuring177 to 230 μm in length and 5 to 7 μm in width, which are sheathed andhave nocturnal periodicity. The microfilariae migrate into lymph and enterthe blood stream reaching the peripheral blood . A mosquito ingests themicrofilariae during a blood meal . After ingestion, the microfilariae losetheir sheaths and work their way through the wall of the proventriculus andcardiac portion of the midgut to reach the thoracic muscles . There themicrofilariae develop into first-stage larvae and subsequently into third-stage larvae . The third-stage larvae migrate through the hemocoel to themosquitos prosbocis and can infect another human when the mosquitotakes a blood meal .
    • • Reservoir of infection: – There is no evidence that W. bancrofti has animal reservoirs in India – Animal reservoirs of Brugia are present in monkeys, cats and dogs• Source of infection: – A person with circulating Mf in peripheral blood – In late obstructive stages Mf are not present in the blood
    • Vectors of lymphatic filariasis• Main vectors in India are: – C. quinquefasciatus for Bancroftian filariasis – Mansonia mosquitoes for Brugian filariasis
    • • Modes of transmission: – Bite of infected vector mosquitoes• Incubation period: – 8-16 months
    • Clinical manifestations• Asymptomatic microfilaraemia• Acute adenolymphangitis (ADL)• Chronic lymphoedema/Elephentiasis• Tropical pulmonary eosinophilia (TPE)
    • Diagnosis• Demonstration of Mf in peripheral blood – Blood collected between 8:30 pm to 12:00 am• DEC provocation test – Blood examined one hour after administration of 100 mg DEC given orally
    • • Antigen detection assays• Serological assays to detect antibodies to Mf and adults using IF and CF techniques – Do not distinguish between past and present infection
    • Parasitological parameters• Microfilaria rate – % of persons showing Mf in their peripheral blood• Filarial endemicity rate – % of persons examined showing Mf in their blood, or clinical manifestations, or both• Microfilarial density – Number of Mf per unit volume (20cumm) of blood• Average infestation rate – Average number of Mf per positive slide
    • Control measures• Chemotherapy – DEC (Diethylcarbamazine) • Selective treatment (6 mg/kg X 12 days) • Mass therapy (MDA) – Ivermectin• Vector control
    • DENGUE(Breakbone fever)
    • WHAT IS DENGUE?• Viral disease (Flavivirus)- four serotypes• Transmitted by the infective bite of Aedes aegypti/Aedes albopictus• Man develops disease after 5-6 days of being bitten by an infective mosquito• Occurs in two forms – Dengue Fever and – Dengue Haemorrhagic Fever(DHF)
    • World-wide dengue distribution, 2006. Red: Epidemic dengue. Blue: Aedes aegypti
    • DISTRIBUTION OF DENGUE/DHF IN INDIA
    • • Disease is prevalent throughout India in most of the metropolitan cities and towns• Outbreaks have also been reported from rural areas of Haryana, Maharashtra & Karnataka
    • CASESDEATHS
    • TRANSMISSION CYCLE OF DENGUE Man-Mosquito-Man
    • VECTOR OF DENGUE/DENGUE HAEMORRHAGIC FEVER• Aedes aegypti• Extrinsic IP= about 7 to 8 days• Feeding Habit – Day biter – Mainly feeds on human beings in domestic and peridomestic situations – Bites repeatedly
    • • RESTING HABIT – Rests in the domestic and peridomestic situations – Rests in the dark corners of the houses, on hanging objects like clothes, umbrella, etc. or under the furniture• BREEDING HABITS – Aedes aegypti mosquito breeds in any type of man made containers or storage containers having even a small quantity of water – Eggs of Aedes aegypti can live without water for more then one year
    • • FAVOURED BREEDING PLACES – Desert coolers, Drums, Jars, Pots, Buckets, Flower vases, Plant saucers, Tanks, Cisterns, Bottles, Tins, Tyres, Roof gutters, Refrigerator drip pans, Cement blocks, Cemetery urns, Bamboo stumps, Coconut shells, Tree holes and many more places where rainwater collects or is stored
    • • PERIOD OF COMMUNICABILITY – Infected person with Dengue becomes infective to mosquitoes 6 to 12 hours before the onset of the disease and remains so upto 3 to 5 days• AGE & SEX GROUP AFFECTED – All age groups & both sexes are affected – Deaths are more in children during DHF outbreak
    • SIGNS & SYMPTOMS OF DENGUE FEVER• Abrupt onset of high fever• Severe frontal headache• Pain behind the eyes which worsens with eye movement• Muscle and joint pains• Loss of sense of taste and appetite• Measles-like rash over chest and upper limbs• Nausea and vomiting
    • SIGNS & SYMPTOMS OF DENGUE HAEMORRHAGIC FEVER AND SHOCK SYNDROME• Symptoms similar to dengue fever• Severe continuous stomach pains• Skin becomes pale, cold or clammy• Bleeding from nose, mouth & gums and skin rashes
    • • Frequent vomiting with or without blood• Sleepiness and restlessness• Patient feels thirsty and mouth becomes dry• Rapid weak pulse• Difficulty in breathing
    • DIAGNOSIS• Tourniquet test (look for the petechiae)• Low platelet count (<100,000/mm3)• Hemoconcentration (Hematocrit increased by 20% or more of the baseline value)
    • MANAGEMENT OF DENGUE CASE• Early reporting• Management of dengue fever is symptomatic & supportive• In dengue shock syndrome, the following treatment is recommended: – Replacement of plasma losses – Correction of electrolyte and metabolic disturbances – Blood transfusion
    • Control of Dengue/ DHF• No drug/vaccine available• Control of Aedes aegypti only method of choice
    • • Vector control measures: – Environmental management & source reduction – Biological control – Chemical control – Personal protection measures – Health education – Community participation
    • DO’S AND DON’TS• Remove water from coolers and other small containers at least once in a week• Use aerosol during day time to prevent the bites of mosquitoes• Do not wear clothes that expose arms and legs• Children should not be allowed to play in shorts and half sleeved clothes• Use mosquito nets or mosquito repellents while sleeping during day time
    • JAPANESE ENCEPHALITIS (JE)
    • What is Japanese Encephalitis?• A viral disease- Flavivirus• Transmitted by infective bites of female mosquitoes mainly belonging to Culex tritaeniorhynchus, Culex vishnui and Culex pseudovishnui group• JE virus is primarily zoonotic in its natural cycle and man is an accidental host• JE virus is neurotorpic and arbovirus and primarily affects central nervous system
    • PROBLEM STATEMENT• Leading cause of viral encephalitis in Asia with 30-50,000 cases reported annually• Fewer than 1 case/year is reported in U.S. civilians and military personnel traveling to and living in Asia
    • • Countries which have had major epidemics in the past, but which have controlled the disease primarily by vaccination • China Korea • Japan Taiwan • Thailand• Countries that still have periodic epidemics • Viet Nam Cambodia • Myanmar India • Nepal Malaysia
    • JE endemic areas
    • Extent of problem of JE in India• JE viral activity has been widespread in India. The first evidence of presence of JE virus dates back to 1952.• First case was reported in 1955• Outbreaks have been reported from different parts of the country.• During recent past (1998-2004), 15 states and Union Territories have reported JE incidence
    • 7000 6000Number of cases 5000 4000 6061 3000 3024 1124 3003 2000 2320 1030 1000 0 2003 2004 2005 2006 2007 2008 AP Assam Bihar Haryana Karnataka Kerala Maharashtra TN UP WB
    • 1800 1600 1400Number of deaths 1200 1000 1500 800 645 600 237 400 528 536 228 200 0 2003 2004 2005 2006 2007 2008 AP Assam Bihar Haryana Karnataka Kerala Maharashtra TN UP WB
    • JE affected districts in India
    • TRANSMISSION CYCLE•Culex- Vector•Pigs- Amplifier host•Ardeid birds (Cattle egret, Pond heron)- Naturalhosts•Man- Dead end (Mosquitoes do not get infectionfrom JE patient)
    • CATTLE EGRET POND HERONReintroduction of infectedmosquitoes or TRITAENORHYNCUS vertebrates PIG Viral CULEX amplification Vertical transmission Infected vertebrate reservoir
    • • Japanese encephalitis outbreaks are usually circumscribed and do not cover large areas• They usually do not last more than a couple of months, dying out after the majority of the pig amplifying hosts have become infected
    • Epidemiological features• Incubation period: – Usually 5 to 15 days• Mortality rate: – Case-fatality rates range from 0.3% to 60% (Usually 20-40%)
    • • Who is at risk for getting Japanese encephalitis? – Residents of rural areas in endemic locations – Active duty military deployed to endemic areas – Expatriates who visit rural areas• Japanese encephalitis does not usually occur in urban areas
    • Clinical features• Febrile illness of variable severity associated with neurological symptoms ranging from headache to meningitis or encephalitis• Ratio of overt disease to inapparent infection varies from 1:300 to 1:1000• Headache, fever, meningeal signs, stupor, disorientation, coma, tremors, paralysis (generalized), hypertonia, loss of coordination
    • • Prodromal stage: – Abrupt (1-6 hours) – Acute (6-24 hours) – Subacute (2-5 days)- more common – Fever, headache, malaise
    • • Acute encephalitic stage: – Usually lasts for a week – Convulsions – Alteration of sensorium – Behavioural changes – Motor paralysis – Involuntary movement – Focal neurological deficit
    • • Convalescent phase: – Prolonged; may vary from a few weeks to several months – Those who survive may fully recover through steady improvement or suffer with residual neurological deficit• JE virus infection presents classical symptoms similar to any other virus causing encephalitis. Clinically it is difficult to differentiate between JE and other viral encephalitis
    • Diagnosis• Clinical• Laboratory – Antibody detection • HI, CF, ELISA for IgG (paired) and IgM (MAC) antibodies – Antigen Detection • RPHA, IFA • Immunoperoxidase • Genome Detection – RTPCR • Isolation – Tissue culture, Infant mice, etc• In view of the limitations associated with various tests, IgM ELISA is the method of choice provided samples are collected 3-5 days after the infection
    • Prevention and control• Vector control: – reducing the vector density – role of insecticides is limited – reduction in mosquito breeding (eco- management; source reduction) – personal protection against mosquito bites – using insecticide treated mosquito nets
    • • Vaccination:Three types of vaccines available – Mouse brain-derived, purified and inactivated, freeze dried vaccine (Nakayama strain) – Cell culture-derived inactivated vaccine (Beijing strain) – Cell culture-derived live attenuated vaccine (SA 14-14-2 strain)
    • Mouse brain-derived inactivated vaccine• Has been used globally • Multiple doses ( 3 Primary successfully to control + Booster) JE • High cost• Safe, efficacious • Low availability • Limited duration of induced• Manufactured in India protection and used in many • CRI may also close down states since 70s the production
    • • Immunization schedule – 2 primary doses 4 weeks apart – Booster after 1 year – Subsequent boosters every 3 years till 10-15 years of age• Route of administration – SUBCUTANEOUS• Dose – 0.5ml (<3 years) – 1 ml (>3 years)
    • SA14-14-2 Live attenuated JE Vaccine• Has been used since 1988 in China• Over 200 million children vaccinated• Safe and efficacious• High immunogenicity following single dose (booster after 1 year)• Licensed in Nepal and South Korea and Thailand – Following this the vaccine has been licensed in India for use in public health programs and is in the final stages of licensing in Sri Lanka• Special cost of vaccine for public program in GAVI eligible countries – Approximately 13 children could be vaccinated with the SA14-14-2 vaccine with the cost of vaccinating one child with the inactivated m-b derived vaccine
    • “A proven immunization strategy for JEcontrol seems to be to initiate a preventivecampaign in high risk areas and age groupsfollowed by introduction of vaccine into theroutine EPI programme”
    • JE Vaccination Strategy for India• Vaccinate all children between the age group of 1-15 years with a single dose of live attenuated SA14-14-2 JE vaccine in a one time campaign• Integration into the routine immunization in the district to cover the new cohort of 1- 2 years
    • • Control of piggeries: – Vaccination of swine – Live/killed vaccines available – Maintaining vaccination coverage is difficult because their population is renewed very rapidly – Piggeries may be kept away (4-5 kms) from human dwellings
    • CHIKUNGUNYA FEVER
    • • Dengue like disease• Flavivirus• Aedes aegypti (Culex?, Mansonia?)• Sub- Saharan Africa, India, Asia• 151 districts in 8 states/UTs have reported cases between Feb 2006 & Oct 2006• South & central India• Karnataka & Maharashtra
    • • Incubation period: – 4-7 days• Clinical features: – Fever, chills, headache, backache – Adenopathy – Rash on trunk and limbs – Arthropathy • Adults • Metacarpophalangeal, wrists, elbow, shoulder, knee, an kle, metatarsal • Can persist for months or even years
    • • No deaths have been reported• Diagnosis by serology (ELISA to detect IgM)• No vaccine available• No specific treatment• Control – Vector control
    • VIRAL HEMORRHAGIC FEVERS
    • • Arenaviridae – Lassa fever• Filoviridae – Marburg hemorrhagic fever, Ebola HF• Flaviviridae – Dengue HF, Yellow fever, KFD• Bunyaviridae – HF with renal syndrome (Hantaan virus), Rift valley fever
    • YELLOW FEVER
    • • Zoonotic disease caused by an arbovirus (Flavivirus, ssRNA)• Viral hemorrhagic fever• Tropical & subtropical regions of Africa & Americas• Historically, accompanied travelers during European colonial period
    • Problem Statement
    • • ETHIOPA – 1 lakh cases, 30000 deaths• GAMBIA – 2.5% prevalence of severe infection, with a CFR of 19%• NIGERIA – 18735 cases, 4522 deaths
    • • No cases reported from Asia where Dengue, a closely related disease is endemic• Dengue immunity ? Cross-protection against yellow fever- Yellow fever immunization does not protect against dengue• INDIA – Population unvaccinated & susceptible to YF – Aedes aegypti is abundant – Climatic conditions are favorable for transmission – Indian monkey (Macacus) is susceptible to YF – ? Missing link-Virus is not present in India
    • Agent factors• AGENT – Flavivirus, ssRNA• RESERVOIR OF INFECTION – Forest areas- Monkeys, Forest mosquitoes – Urban areas- Man, Aedes aegypti• PERIOD OF COMMUNICABILITY – Man- 1st 3-4 days of illness – Mosquitoes- 8-12 days Extrinsic IP – Transovarian transmission documented
    • Host factors• AGE & SEX – All ages & both sexes susceptible• OCCUPATION – Contact with forests (wood cutters, hunters)• IMMUNITY – One attack gives life-long immunity
    • Environmental factors• CLIMATE – >24⁰C, 60% RH- required fro multiplication of virus in the mosquito• SOCIAL FACTORS – Urbanization – Forest encroachment – Expanding population – Travel- frequency and speed
    • Modes of transmission Three types of transmission cycle for yellow fever• Sylvatic (or Jungle) yellow fever – Monkeys• Intermediate yellow fever – Monkeys & humans• Urban yellow fever – Humans
    • • Sylvatic (or Jungle) yellow fever- Africa & America – Occurs in monkeys infected by wild mosquitoes (Haemagogus in America; Aedes africanus in Africa) in tropical rainforests – Infected monkeys pass the virus to mosquitoes during feeding – Infected wild mosquitoes bite humans entering the rainforest (accidental infection)- Sporadic cases – The majority of cases are young men working in the forest (logging, etc) – On occasion, the virus spreads beyond the affected individual
    • • Intermediate yellow fever- Africa – Small-scale epidemics that occur in humid or semi-humid grasslands of Africa – Separate villages experience simultaneous infections transmitted by semi-domestic mosquitoes that infect both monkey and human hosts – Most common type of outbreak in Africa – It can shift to a more severe urban-type epidemic if the infection is carried into a suitable environment (with the presence of domestic mosquitoes and unvaccinated humans)
    • • Urban yellow fever- Africa & America – Large epidemics occurring when the virus is introduced into high human population areas by migrants – Domestic mosquitoes of one species (Aedes aegypti) transmit the virus from person to person – Monkeys are not involved in transmission – Outbreaks spread from one source to cover a wide area
    • Incubation period• 3-6 days• SIX days recognized for International Health Regulations
    • Clinical features• Mild, undifferentiated fever to severe illness• Hemorrhagic, hepatic & renal manifestations predominate• Jaundice- develops after 4-6 days of illness• Renal Tubular Necrosis- during 2nd week• Albuminuria, Anuria• Hemoptysis, Melena, Epistaxis• Death between 5th & 10th day of illness
    • Prevention & Control1. Treatment – No specific treatment for yellow fever – ORS and paracetamol for dehydration and fever – An appropriate antibiotic(s) for any superimposed bacterial infection – Intensive supportive care may improve the outcome for seriously ill patients, but is rarely available in poorer, developing countries
    • 2. Vaccination – Type of vaccine • Live attenuated freeze dried chick embryo • 17D vaccine – Dose • One dose of 0.5 ml subcutaneously – Schedule • Routine immunization with measles vaccine at nine months of age
    • – Booster • International health regulations require a booster every 10 years– Contraindications • Egg allergy • Immune deficiency from medication or disease • Symptomatic HIV infection • Hypersensitivity to previous dose • Pregnancy*
    • – Special pecautions • Do not give before six months of age • Avoid during pregnancy • Cholera & YF vaccines should be given at least 3 weeks apart– Adverse effects • Hypersensitivity to egg • Rarely, encephalitis in the very young • Hepatic failure • Yellow fever vaccine-associated viscerotropic disease; among older recipients
    • – Storage • Between +5 & -30 deg C, preferably below ZERO deg C • Saline diluent • Discarded if not used within half an hour of dilution • Kept on ice away from sunlight
    • – Validity • The validity of yellow fever vaccination certificate begins 10 days after the date of vaccination and extends up to 10 years– India requires vaccination of infants too
    • 3. Vector control – Anti-adult measures – Anti-larval measures – “Source reduction”- Elimination of breeding places – Personal protection – Health education- for community involvement
    • 4. Surveillance – Clinical – Serological – Histopathological – Entomological – “Aedes aegypti Index” • The percentage of houses & their premises, in a limited well-defined area, showing actual breeding of Aedes aegypti larvae • This index should not be more than 1% in towns & seaports in endemic areas
    • 5. International measures – “Yellow fever receptive area”- An area in which YF is does not exist, but where conditions would permit its development if introduced – Valid international YF vaccination certificate for travelers to endemic areas or traveling through such areas – If not present, QUARANTINE for 6 days – Aerosol spraying of ships & aircraft from endemic areas – AEI kept below 1% at airports & seaports (kept free from breeding places over 400 m area around their perimeters)
    • KAYASANUR FOREST DISEASE (KFD)
    • • Viral hemorrhagic fever• Arboviral; Flavivirus• Transmitted to man by bite of infective ticks (Haemaphysalis)• Karnataka in 1957• 2167 cases & 69 deaths in 1983-84• 306 cases & 11 deaths in 2003
    • Epidemiological determinants• AGENT – Tick-borne flavivirus• NATURAL HOSTS & RESERVOIR – Main reservoirs- Rats & squirrels – Amplifying host- Monkeys – Man is an incidental or dead-end host – Cattle- Provide blood meals for ticks; important in maintaining tick populations
    • • VECTORS – Haemaphysalis spinigera, H turtura – Nymph stages – January to June- Highest number of infections; peak nymphal activity of ticks• HOST FACTORS – Age- 20-40 years – Sex- Males>Females – Occupation- involving forest visits – Human activity- Forest activity; Jan to June
    • • MODE OF TRANSMISSION – Transmission cycle involves monkeys and ticks – No evidence of man to man transmission• INCUBATION PERIOD – 3-8 days
    • Clinical features• Sudden onset fever, headache and severe myalgia• Acute phase for 2 weeks• GI disturbances and hemorrahges• SECOND PHASE – Mild meningoencephalitis after an afebrile period of 7-21 days• CFR= 5-10%
    • Diagnosis• Presence of virus in blood• Serology
    • CONTROL• CONTROL OF TICKS – Carbaryl/Fenthion/Propoxur – Carried out in “hot spots” ( areas where monkey deaths have been reported) – Restriction of cattle movement
    • • PERSONAL PROTECTION – Adequate clothing – Insect repellents (DEET) – Remove ticks from body and clothing at the end of the day – Discourage lying down or sitting on ground• VACCINATION – Killed vaccine
    • Leishmaniasis
    • • A group of protozoal diseases caused by parasites of the genus Leishmania, and transmitted to man by the bite of female phlebotomine sandfly• Majority of leishmaniasis are zoonoses involving wild or domestic mammals (rodents, canines)• Indian kala-azar is considered to be a non- zoonotic infection
    • • Visceral leishmaniasis (VL)• Cutaneous leishmaniasis (CL)/Oriental sore• Muco-cutaneous leishmaniasis (MCL)
    • Problem statement• Visceral leishmaniasis Bangladesh India Brazil Sudan• Cutaneous leishmaniasis Afghanistan Iran Brazil Peru Saudia Arabia Syria• Muco-cutaneous leishmaniasis Brazil Bolivia Peru
    • • Endemic in 88 countries• Co-infection of VL & AIDS is emerging due to spread of the AIDS pandemic particularly in southern Europe, where 25-70% of adult VL cases are related to HIV infection, & 1.5-9% of AIDS patients suffer from newly acquired or reactivated VL
    • Indian scenario• Kala-azar (VL) Bihar Jharkhand West Bengal Uttar Pradesh (eastern)• Cutaneouos Leishmaniasis North-western India (Rajasthan)
    • • Both cutaneous and visceral diseases occur in India• Kala-azar is the most important leishmaniasis in India
    • Epidemiological determinants• AGENT: – VL (Kala-azar) • Leishmania donovani – CL (Oriental sore) • L. tropica • L. major – MCL • L. braziliensis
    • • Sandfly injects the promastigote stage into skin• Promastigotes transform into amastigotes (LD bodies) inside the macrophages (human)• Sandfly ingests amastigotes• Amastigotes transform into promastigote stage inside the sandfly midgut, divide & migrate to proboscis
    • • RESERVOIRS OF INFECTION: – Rodents, dogs, jackals, foxes etc – Indian kala-azar is considered to be a non- zoonotic infection with man as the only reservoir
    • • HOST FACTORS: – Kala-azar can occur in all age groups. Peak age in India is 5-9 years – Males are affected twice as often as females – Population movement can result in spread of infection from non-endemic to endemic areas – Lower socio-economic class – Farming practices, forestry, mining, fishing etc are risk occupations
    • • ENVIRONMENTAL FACTORS: – Kala-azar is mostly confined to the planes; does not occur in altitudes over 2000 feet – Generally there is a high prevalence during & after rains – Generally confined to rural areas – Overcrowding – Ill-ventilation – Accumulation of organic matter in the environment
    • Vector• Kala-azar – Phlebotomus argentipes• CL – P. papatasi – P. sergenti• New world – Lutzomyia species
    • • Sandflies breed in cracks and crevices in the soil & buildings, tree holes, caves etc• They have nocturnal habits• Only females bites
    • Mode of transmission• Bite of the female phlebotomine sandfly (P. argentipes/papatasi/sergenti)• By contact when the insect is crushed during the act of feeding• Extrinsic IP = 6-9 days• Transmission of kala-azar has also been recorded by blood transfusion
    • Incubation period• 1 to 4 months (10 days to 2 years)
    • Clinical features• Kala-azar: – Fever – Splenomegaly – Hepatomegaly – Anaemia – Weight loss – Darkening of skin (face, hands, feet, abdomen)
    • • PKDL (Post-kala-azar Dermal Leishmaniasis): – Common in India – Occurs one to several months after apparent cure of kala-azar – Multiple nodular infiltrations of the skin – Numerous parasites in the skin lesions; important in disease transmission
    • • Cutaneous leishmaniasis: – Painful ulcers in areas of skin exposed to sandfly bite (legs, arms, face)• Muco-cutaneous leishmaniasis: – Ulcers around mouth & nose – Can mutilate the face
    • Laboratory diagnosis• Demonstration of the parasite LD bodies (Leishman-Donovan body) in the aspirates of spleen, liver, bone marrow, LNs, or in the skin (in CL)
    • • Napier’s Aldehyde test – 1-2 ml of serum + 40% formalin – White opacity within 2-20 min = strongly positive – Becomes positive 2-3 months after onset of disease, & reverts to negative 6 months after cure – Non-specific• Serology – ELISA
    • • Leishmanin test (Montenegro test) – Leishmanin is a prepration of 106 per ml washed promastigotes of leishmania suspended in 0.5% phenol – An intradermal injection of 0.1 ml on the flexor aspect of forearm is given and examined after 48- 72 hours
    • – An induration of 5 mm or more is considered positive– The test is usually positive 4-6 weeks after onset in case of CL and MCL– Usually negative in the active phases of kala-azar & becomes positive in 75% cases within one year of recovery
    • • Haematological findings: – Leucopenia – Anaemia – Reversal of A:G ratio – Decreased WBC:RBC ratio (1:1500 or more) – Increased ESR
    • Control measures• Control of reservoir• Sandfly control• Personal protection
    • Control of reservoir• Man – Active & passive case detection – Treatment of those found to be infected (including PKDL) • Sodium stibogluconate – 20mg/kg (max 850 mg) IM/IV X 20 days • Pentamidine – (3mg/kg) IV X 10 days • Amphotericin B • Miltefosine
    • Sandfly control• Insecticides – DDT – Spraying should be undertaken in human dwellings, animal shelters, & all other resting places up to a height of 6 feet from floor level
    • • Sanitation measures – Elimination of breeding places (cracks in mud or stone walls, rodent burrows, removal of firewood, rubbish around the house) – Location of cattle sheds & poultry at a fair distance from human dwellings – Improvement of housing & general sanitation
    • Personal protection• Avoiding sleeping on floor• Using fine-mesh nets around the bed• Insect repellents• Health education• There are no drugs for personal prophylaxis
    • NVBDCP (National Vector Borne Diseases Control Program)
    • • Malaria• Filariasis• Kala-azar• Japanese encephalitis• Dengue• Chikungunya
    • Three pronged strategy:• Disease management – Early case detection and complete treatment – Strengthening of referral services – Epidemic preparedness and rapid response
    • • Integrated vector management – Indoor residual spraying – Insecticide treated bed nets – Larvivorous fish – Source reduction and minor environmental engineering
    • • Supportive interventions – Behavior change communication – Public private partnership & intersectoral convergence – Human resource development – Operational research – Monitoring and evaluation
    • MALARIA
    • • National Malaria Control Program – 1953• National Malaria Eradication Program – 1958• Modified Plan of Operations (MPO) – 1977• National Anti-Malaria Program – 1999
    • • Objectives of MPO: – Consolidation of the achievements already made in the containment of malaria – Prevention of malaria mortality and reduction of malaria morbidity – Maintenance of agricultural and industrial productivity by intensive operations in the labor- intensive endemic areas
    • • Organization and implementation: – Integration of the malaria organization with the state health system – Reinforcement • District Malaria Officer • Malaria laboratory in every PHC • Fever Treatment Depots (FDT) - (Smear+Drugs) • Drug Distribution Centers (DDC) - Drugs
    • • Operational details: – For API 2 or more areas • Regular insecticidal spraying – 2 DDT (1g/sq m) OR 3 Malathion (2 g/sq m) OR 2 Synthetic pyrethroids (0.25g/sq m) • Entomological assessment • Surveillance (active & passive) • Treatment of cases
    • – For API less than 2 areas • Focal spraying around Pf cases detected • Surveillance • Treatment • Follow-up • Epidemiological investigation
    • • Area-based initiatives: – Enhanced Malaria Control Project (EMCP) • Tribal population • 100 districts in 8 states • 100% assistance through World Bank support • 1997 – 2005 • 48 districts achieved an API of less than 2
    • – Intensified Malaria Control Project • Launched in 2005 with assistance from ‘Global Fund for AIDS, Tuberculosis, and Malaria’ • Increase access to rapid diagnosis & treatment through community participation • Use of ITNs • Vector control by larvivorous fish • NGO & private sector participation
    • – Assistance to NE states • 100% central assistance to NE states
    • • Activity-based initiatives: – Indoor Residual Spraying – Insecticide-treated bed-nets – Larvivorous fish use – Case detection and treatment
    • • Present strategies for prevention and control of malaria1. Early case Detection and Prompt Treatment (EDPT)2. Vector control3. Community Participation4. Environmental Management & Source Reduction Methods5. Monitoring and Evaluation of the program
    • • Annual parasite incidence (API)• Annual blood examination rate (ABER)• Annual falciparum incidence (AFI)• Slide positivity rate (SPR)• Slide falciparum rate (SFR)
    • MALARIA CONTROL
    • Two different approaches to malaria control• Management of malaria cases in the community• Active intervention to control or interrupt malaria transmission with community participation
    • Management of malaria cases in the community• Case detection• Treatment – Uncomplicated malaria • Plasmodium vivax • Plasmodium falciparum – Severe and complicated malaria• Chemoprophylaxis
    • Case detection• Active and passive case detection• Fever cases presumed to be suffering to be suffering from malaria, unless proved otherwise• In case laboratory diagnosis is not immediately available, differential diagnosis on clinical grounds should be made
    • Treatment• Any fever in endemic areas during transmission season without any other obvious cause should be considered as malaria and investigated and treated accordingly• Drug resistance are present in country, but chloroquine is still safe and effective• The best approach in malaria control is diagnosis and treatment on the same day
    • Treatment: Uncomplicated malaria• Plasmodium vivax cases – Day 0: T. Chl 10 mg/kg BW (600 mg adult dose) – Day 1: T. Chl 10 mg/kg BW (600 mg adult dose) – Day 2: T. Chl 5 mg/kg BW (300 mg adult dose) PLUS T. Primaquin 0.25 mg/kg BW daily for 14 days• Plasmodium falciparum cases • Chloroquin sensitive areas – Day 0: T. Chl 10 mg/kg BW (600 mg adult dose) – Day 1: T. Chl 10 mg/kg BW (600 mg adult dose) – Day 2: T. Chl 5 mg/kg BW (300 mg adult dose) THEREAFTER T. Primaquin 0.75 mg/kg BW single dose
    • Treatment: Uncomplicated malaria• Plasmodium falciparum cases • Chloroquin resistant areas • Give ACT (Artesunate Combination Therapy) • T. Artesunate 4mg/kg BW daily X 3days PLUS • T. Sulphadoxine 25 mg/kg BW and T. Pyrimethamin 1.25 mg/kg BW on the first day (Contraindicated in pregnant females) THEREAFTER T. Primaquin 0.75 mg/kg BW single dose • Resistance to Chloroquine and ACT • Oral Quinine 10 mg/kg BW and T. Doxycycline 100 mg daily for 3 days THEREAFTER T. Primaquin 0.75 mg/kg BW single dose
    • Treatment: In severe and complicated malaria• Cases should be hospitalized for treatment – Quinine – Artesunate Followed by full – Artemether course of ACT – Artether – Use of Mefloquin alone or in combination with artesunate should be avoided in cerebral malaria due to neuro-psychiatric complications associated with it.
    • Chemoprophylaxis• Travelers from non-endemic areas• Soldiers serving in highly endemic areas• Migrant labourers• Should be complemented by personal protection and environmental measures• Intermittent preventive treatment in pregnancy
    • Chemoprophylaxis• For short-term prophylaxis (< 6 weeks) – Doxycycline 100 mg X OD in adults or 1.5 mg/kg BW for children >8 years old. – Started 2 days before travel and continued for 4 weeks after leaving the malarious area. – Contraindicated in pregnant females and children <8 years.• For long-term prophylaxis (>6 weeks) – Mefloquine 5 mg/kg BW (upto 250 mg) weekly – Started 2 weeks before travel and continued till 4 weeks of leaving the malarious area. – Contraindicated in cases with H/O convulsions, neuropsychiatric problems and cardiac conditions.
    • Active intervention measures• Stratification of the problem• Vector control strategies – Anti-adult measures – Anti-larval measures• Malaria vaccines
    • Stratification of the problem• For planning and development of a sound control strategy to maximize the utilization of available resources• Stratification is based on API – Areas with API<2 – Areas with API>2
    • Vector control strategies• Anti-adult measures – Residual spraying – Personal protection measures • ITN • LLITN • Repellents • Protective clothing • Screening of houses
    • • Anti-larval measures – Source reduction – Larvicides • Oils • Paris green • Insecticides (Temephos) – Integrated control
    • Malaria vaccines• Pre-erythrocytic vaccines• Blood-stage vaccines• Transmission-blocking vaccines – Pfs25• Cocktail vaccines – SPf66
    • FILARIASIS
    • • National Filaria Control Program – 1955 – Implemented through • Filaria control units Endemic • Filaria clinics urban towns • Survey units • Though PHc system in rural areas – Filaria control strategy • Vector control • Detection & treatment of microfilaria carriers • Morbidity management • IEC
    • • WHA resolution of 1997 – global elimination of lymphatic filariasis• Elimination of filariasis by 2015 – Revised filaria control strategy • Annual MDA – Single dose DEC (6mg/kgBW) for 5 years or more to ‘at risk population’ excluding pregnant females, children <2 years of age, seriously ill patients • Case management • Capacity building • Social mobilization
    • Kala-azar
    • • Strategies for Kala-azar elimination are: – Enhanced case detection and complete treatment (including rapid diagnostic kits, miltefosine) – Vector control – BCC and intersectoral convergence – Capacity building – Monitoring, supervision and evaluation – Research
    • • In may 2005, a tripartite MoU between India, Nepal & Bangladesh; to reduce the annual incidence of Kala-azar to <1/10000 population at sub-district level by 2015.• National Health Policy envisages Kala-azar elimination by 2010.
    • Dengue and Chikungunya
    • • Case management – Health personnel training- upgrading clinical skills and diagnostic competence• Health education – Community is informed on the characteristic features of the disease and the facilities available for their clinical management• Vector control – Elimination of vector breeding sites – Disposing of all the junk material that collects water & encourages vector breeding – Keeping all water containers and storage facilities tightly covered – Cleaning the water coolers at least once a week before refilling• Monitoring and surveillance
    • JAPANESE ENCEPHALITIS
    • • Operational strategy: – Early case detection and prompt management – Vector density reduction by adulticidal and larvicidal measures – IEC campaigning for community participation – Immunization of high-risk population groups
    • 233